Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

According to reporting from the BBJ, VC funding in June was lighter than usual; however, when it came to M&As, Boston biotechs were busy.

Detailed price information for Atai Life Sciences N.V. (ATAI-Q) from The Globe and Mail including charting and trades.

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

Review Sage Therapeutics Inc (SAGE:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.